A Dose-Finding Study of MM-120 for the Treatment of Anxiety Symptoms

This is a Phase II, multi-centre, randomized, double-blind, parallel-group, dose-finding study to assess the effect of four doses of MM-120 (25, 50, 100 or 200 μg LSD freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).

Topic Anxiety
Compound LSD
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

MindMed
MindMed is one of the largest companies in the psychedelics space and is developing various psychedelics for mental health disorders.

Papers

Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial
This Phase IIb randomised, double-blind, placebo-controlled trial (n=198) found that single doses of 100 µg and 200 µg of MM120 (lysergide D-tartrate) significantly reduced anxiety symptoms at 4 weeks in adults with moderate to severe generalised anxiety disorder (GAD), with dose-dependent effects and adverse events including visual perceptual changes, nausea, and headache.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.